Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007

Bone Marrow Transplantation

Volumn 42, Issue SUPPL.1, 2008, Pages

  Goldman, J M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; CYTOTOXIC AGENT; DASATINIB; IMATINIB; INTERFERON; NILOTINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MONOTHERAPY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS;

EID: 50549102799     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.105     Document Type: Review

References (20)

1. Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H et al Disappearance of Phil-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979; 300 333-337.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med 2006; 355: 2408-2417.
4. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic bode marrow transplantation. Lancet 1998; 352 1087-1092.
5. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA, Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613-620.
6. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F et al Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001; 115: 569-574.
7. Goldman JM, Sobocinski KA, Zhang KA, Klein JP, Ketelsen SW, Giralt SA et al. Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 17 (abstract 40).
8. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplant for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2006; 91: 513-521.
9. Giralt S, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic leukaemia. Br J Haematol 2007; 137: 461-467.
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
11. Baccarani M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-net. Blood 2006; 108: 1809-1820.
12. Deininger M, Schleuning M, Greinix H, Sayer H, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452-459.
13. Oehler VG, Gooley T, Synder DS, Johnston L, Lin A, Cummings CC et al The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109 1782-1789.
14. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
15. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ. The graft versus leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897-901.
16. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after non-myeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101: 469-472.
17. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083-1088.
18. Crawley C, Szydio R, Lalancette M, Bacigalupo A, Lange A, Brune M, Chronic Leukemia Working Party of the EBMT et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005; 106: 2969-2976.
19. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT) et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707-1712.
20. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91 663-666.